Aastrom Biosciences Inc., of Ann Arbor, Mich., received U.S. Patent No. 6,835,566, expanding coverage of the company's single-pass perfusion technology to cover enhancing biological functionality of human dendritic cells produced in cell cultures.

Acologix Inc., of Emeryville, Calif., received U.S. Patent No. 6,818,745 titled "Novel Polypeptide Hormone Phosphatonin," covering composition and use of the compound the company is developing for treating chronic kidney disease.

Active Biotech, of Lund, Sweden, received a notice of allowance for its TTS cancer project, allowing the possibility to use TTS as combination therapy. The patent is valid until 2018.

Agilix Corp., of New Haven, Conn., was granted U.S. Patent No. 6,824,981 titled "Ultra-Sensitive Detection Systems Using Alterable Peptide Tags," for isobaric protein labeling, part of Agilix's i-PROT labeling technology.

Applied Biosystems Group, of Foster City, Calif., received U.S. Patent No. 6,814,934 pertaining to real-time PCR instrumentation.

Biophan Technologies Inc., of Rochester, N.Y., received a patent to secure the rights to its anti-antenna technology for use in magnetic resonance imaging procedures.

Bone Care International Inc., of Middleton, Wis., received a notice of allowance for claims relating to stabilized hydroxyvitamin D2 products and pharmaceutical compositions and medicines including stabilized hydroxyvitamin D2.

No Comments